MENTAX-TC Drug Patent Profile
✉ Email this page to a colleague
When do Mentax-tc patents expire, and when can generic versions of Mentax-tc launch?
Mentax-tc is a drug marketed by Norvium Bioscience and is included in one NDA.
The generic ingredient in MENTAX-TC is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mentax-tc
A generic version of MENTAX-TC was approved as butenafine hydrochloride by TARO on November 16th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MENTAX-TC?
- What are the global sales for MENTAX-TC?
- What is Average Wholesale Price for MENTAX-TC?
Summary for MENTAX-TC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 70 |
| Patent Applications: | 4,050 |
| DailyMed Link: | MENTAX-TC at DailyMed |
US Patents and Regulatory Information for MENTAX-TC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | MENTAX-TC | butenafine hydrochloride | CREAM;TOPICAL | 021408-001 | Oct 17, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
